呼吸频率-氧合指数在COVID-19相关呼吸衰竭患者中的验证
该研究为回顾性验证,纳入2020年2月1日至12月31日期间Kaiser Permanente Northern California 21家医院中SARS-CoV-2 PCR阳性且无生命支持限制的成人患者,共1847例。在HFNC启动后12小时计算ROX指数,按既往阈值分为低危(≥4.88)、中危(<4.88且≥3.85)和高危(<3.85)。525例(31.7%)住院期间接受有创机械通气,511例(27.7%)死亡。12小时ROX<3.85预测有创机械通气的敏感性32.3%(95%CI 28.5-36.3%)、特异性89.8%(95%CI 88.0-91.4%)、阳性预测值59.4%(95%CI 53.8-64.9%)、阴性预测值74.1%(95%CI 71.8-76.3%)。作者指出其医疗系统已将ROX嵌入电子病历,用于住院患者激增期间优先查房。
要点
- 在COVID-19相关呼吸衰竭接受HFNC的成人中,12小时ROX<3.85预测有创机械通气的阳性预测值为59.4%(95%CI 53.8-64.9%),特异性89.8%(95%CI 88.0-91.4%)。
- 12小时ROX<3.85预测有创机械通气的敏感性为32.3%(95%CI 28.5-36.3%),阴性预测值为74.1%(95%CI 71.8-76.3%)。
- 研究队列1847例中,525例(31.7%)住院期间接受有创机械通气,511例(27.7%)死亡。
- ROX指数按既往阈值分为低危(≥4.88)、中危(<4.88且≥3.85)和高危(<3.85)。
- 作者所在医疗系统已将ROX嵌入电子病历,用于住院患者激增期间优先查房。
适用人群与场景
- 2020年2月1日至12月31日期间,Kaiser Permanente Northern California 21家医院中,SARS-CoV-2 PCR检测阳性(住院前3周内或住院期间)且无生命支持限制的成人患者。
诊断标准与关键阈值
- ROX指数在HFNC启动后12小时计算。
- 按既往发表阈值分组:低危(≥4.88)、中危(<4.88且≥3.85)、高危(<3.85)。
研究设计与关键结果
- 研究类型:回顾性验证ROX指数;样本量1847例;21家医院;人群为COVID-19相关呼吸衰竭接受HFNC的成人。
- 主要终点:12小时ROX<3.85预测住院期间任何时间接受有创机械通气的敏感性32.3%(95%CI 28.5-36.3%)、特异性89.8%(95%CI 88.0-91.4%)、阳性预测值59.4%(95%CI 53.8-64.9%)、阴性预测值74.1%(95%CI 71.8-76.3%)。
- 关键次要终点:525例(31.7%)接受有创机械通气,511例(27.7%)死亡。
证据类型、等级与局限
- 证据类型:回顾性验证研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者指出其医疗系统已将ROX嵌入电子病历,用于住院患者激增期间优先查房。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: The respiratory rate-oxygenation (ROX) index is a fraction of oxygen saturation, Fio2, and respiratory rate that has been validated to predict receipt of invasive mechanical ventilation in patients receiving high-flow nasal cannula (HFNC). This study aimed to validate ROX in a cohort of inpatients with COVID-19-related respiratory failure.
DESIGN: Retrospective validation of the ROX index. We calculated sensitivity, specificity, positive predictive value, negative predictive value, and 95% CIs of ROX for invasive mechanical ventilation any time during hospitalization.
SETTING: Twenty-one hospitals of Kaiser Permanente Northern California, an integrated healthcare delivery system.
PATIENTS: We identified adults with positive severe acute respiratory syndrome coronavirus 2 polymerase chain reaction test within 3 weeks of, or during, hospitalization between February 1, 2020, and December 31, 2020. We calculated ROX at 12 hours after HFNC initiation. We grouped patients as low (≥ 4.88), intermediate (< 4.88 and ≥ 3.85), or high (< 3.85) risk using previously published thresholds.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We identified 1,847 patients who had no limitation of life support. Of these, 525 (31.7%) received invasive mechanical ventilation any time during hospitalization and 511 died (27.7%). The sensitivity, specificity, positive predictive value, and negative predictive value of 12-hour ROX threshold (< 3.85) predicting invasive mechanical ventilation were 32.3% (95% CI, 28.5-36.3%), 89.8% (95% CI, 88.0-91.4%), 59.4% (95% CI, 53.8-64.9%), and 74.1% (95% CI, 71.8-76.3%), respectively.
CONCLUSIONS: The 12-hour ROX index has a positive predictive value (59.4%) using threshold of less than 3.85 for COVID-19 patients needing invasive mechanical ventilation. Our health system has embedded ROX into the electronic health record to prioritize rounding during periods of inpatient surge.
参考来源
- Myers LC, Mark D, Ley B, et al. Validation of Respiratory Rate-Oxygenation Index in Patients With COVID-19-Related Respiratory Failure. Crit Care Med. 2022. PMID: 35120044. doi:10.1097/CCM.0000000000005474
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。